pancreatic cancer, photodynamic therapy (PDT), Photogen, DongSeong Pharmaceuticals, clinical trial
JSK Biomed announced the presentation of the latest clinical research results on Mirajet at the '2024 KSDS International Conference (KSDS 2nd International Congress 2024)' held from the 7th to the 9th.
Mirajet, commercialized by JSK Biomed in 2020, is a needle-free drug delivery device that uses a laser-guided method. Utilizing the intense pressure generated when a 2940nm Er
laser meets water and explodes instantaneously, it converts the medication in the syringe into a micro-jet form, delivering it uniformly and quickly to the skin layers.
According to JSK Biomed, Mirajet can inject a precise amount of medication into specific areas while minimizing side effects such as thermal burns, needle pain, and bruising compared to traditional drug delivery methods. This makes it safe for use on sensitive areas around the nose and eyes.
During the conference, JSK Biomed operated a booth and provided online lectures, live seminars, and session presentations to convey Mirajet's unique features. Notably, Dr. Seokbae Seo of Seoasong Dermatology Clinic, an expert on Mirajet, presented various clinical cases at the Pre-congress Workshop held at Seoul St. Mary's Hospital on the 7th, targeting an audience of about 50 domestic and international medical professionals. He also shared his expertise through live demonstrations.
It is reported that overseas medical professionals showed great interest in Mirajet. Dr. Sonja Sattler, a globally renowned anti-aging expert from Germany, officially invited to the conference, commented, "Mirajet has shown remarkable clinical results in treating scars and stretch marks, and even in the field of total anti-aging care, by precisely adjusting various effective medications to suit the patient's skin type. It is a technology that holds great promise for the future."
Junwoo Jeon, CEO of JSK Biomed, said, "Many positive developments are happening, such as the recent publication of clinical research results in papers. It was significant to present our preparations to domestic and international medical professionals at this conference and receive extensive feedback." He added, "Based on this success, we will invest more in future clinical research to maintain our title as 'The One & Only' in the industry."
